Opinion

Video

Patient Selection for Chemotherapy-Based Combination Regimens in Metastatic Prostate Cancer

Key Takeaways

  • Chemotherapy is often selected for aggressive or advanced-stage cancers requiring rapid tumor reduction.
  • Patients with specific genetic mutations may benefit more from targeted therapies than chemotherapy.
SHOW MORE

The panelist discusses how patient characteristics, disease factors, and individual health status guide the decision to include or avoid chemotherapy in combination treatments for metastatic prostate cancer, weighing potential benefits against risks and quality of life considerations.

Related Videos
1 expert in this video
1 expert in this video
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.